PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma
Copyright © 2023 Avilés-Salas, Cabrera-Miranda, Hernández-Pedro, Vargas-Lías, Samtani, Muñoz-Montaño, Motola-Kuba, Corrales-Rodríguez, Martín, Cardona, Palomares-Palomares and Arrieta..
Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelioma (MPM) remains unclear. Evidence suggests that higher PD-L1 expression is correlated with worse survival. CALGB is the main scoring system used to predict the benefit of chemotherapy treatment. This study aimed to determine the prognostic value of PD-L1 expression and its addition to CALGB scoring system in patients with MPM.
Methods: In this retrospective analysis, we evaluated samples with confirmed locally advanced or metastatic MPM. PD-L1 Tumor Proportional Score (TPS) was determined by immunohistochemistry at diagnosis.
Results: 73 patients were included in this study. A cutoff value of 15 was set for a high or low PD-L1 TPS. In total, 71.2% (n=52) and 28.8% (n=21) of individuals harbored low or high PD-L1 expression, respectively. PD-L1High was associated with worse median progression-free Survival (mPFS) [4.9 vs. 10.8 months; HR 2.724, 95% CI (1.44-5.14); p = 0.002] and Overall Survival (OS) [6.0 vs. 20.9 months; HR 6.87, 95% CI (3.4-8.7); p<0.001] compared to patients with PD-L1Low. Multivariate analysis confirmed that PD-L1 expression was an independent factor for PFS and OS in patients with MPM and CALGB score of 5-6.
Conclusion: PD-L1 addition to CALGB scale improves its prognostic estimation of MPM survival and should be considered in future research.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 13(2023) vom: 28., Seite 1269029 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Avilés-Salas, Alejandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CALGB |
|---|
| Anmerkungen: |
Date Revised 20.12.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2023.1269029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366022318 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366022318 | ||
| 003 | DE-627 | ||
| 005 | 20231227134949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2023.1269029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1233.xml |
| 035 | |a (DE-627)NLM366022318 | ||
| 035 | |a (NLM)38111532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Avilés-Salas, Alejandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.12.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Avilés-Salas, Cabrera-Miranda, Hernández-Pedro, Vargas-Lías, Samtani, Muñoz-Montaño, Motola-Kuba, Corrales-Rodríguez, Martín, Cardona, Palomares-Palomares and Arrieta. | ||
| 520 | |a Background: Programmed death ligand-1 (PD-L1) expression is a predictive biomarker in patients with lung cancer, but its role in malignant pleural mesothelioma (MPM) remains unclear. Evidence suggests that higher PD-L1 expression is correlated with worse survival. CALGB is the main scoring system used to predict the benefit of chemotherapy treatment. This study aimed to determine the prognostic value of PD-L1 expression and its addition to CALGB scoring system in patients with MPM | ||
| 520 | |a Methods: In this retrospective analysis, we evaluated samples with confirmed locally advanced or metastatic MPM. PD-L1 Tumor Proportional Score (TPS) was determined by immunohistochemistry at diagnosis | ||
| 520 | |a Results: 73 patients were included in this study. A cutoff value of 15 was set for a high or low PD-L1 TPS. In total, 71.2% (n=52) and 28.8% (n=21) of individuals harbored low or high PD-L1 expression, respectively. PD-L1High was associated with worse median progression-free Survival (mPFS) [4.9 vs. 10.8 months; HR 2.724, 95% CI (1.44-5.14); p = 0.002] and Overall Survival (OS) [6.0 vs. 20.9 months; HR 6.87, 95% CI (3.4-8.7); p<0.001] compared to patients with PD-L1Low. Multivariate analysis confirmed that PD-L1 expression was an independent factor for PFS and OS in patients with MPM and CALGB score of 5-6 | ||
| 520 | |a Conclusion: PD-L1 addition to CALGB scale improves its prognostic estimation of MPM survival and should be considered in future research | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CALGB | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a mesothelioma | |
| 650 | 4 | |a prognostic factor | |
| 700 | 1 | |a Cabrera-Miranda, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Pedro, Norma |e verfasserin |4 aut | |
| 700 | 1 | |a Vargas-Lías, Diana Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Samtani, Suraj |e verfasserin |4 aut | |
| 700 | 1 | |a Muñoz-Montaño, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Motola-Kuba, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Corrales-Rodríguez, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Cardona, Andrés F |e verfasserin |4 aut | |
| 700 | 1 | |a Palomares-Palomares, Cittim B |e verfasserin |4 aut | |
| 700 | 1 | |a Arrieta, Oscar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 13(2023) vom: 28., Seite 1269029 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g day:28 |g pages:1269029 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2023.1269029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |b 28 |h 1269029 | ||